中华皮肤科杂志

• 论著 • 上一篇    下一篇

抗人白介素8单克隆抗体乳膏治疗湿疹的多中心随机双盲对照研究

崔盘根1, 林麟1, 毕志刚2, 骆丹2, 张福仁3, 田洪清3, 连石4   

  1. 1.中国医学科学院皮肤病研究所、中国协和医科大学皮肤病医院;
    2.南京医科大学第一附属医院;
    3.山东省皮肤病医院;
    4.首都医科大学宣武医院
  • 收稿日期:2005-12-23 出版日期:2006-04-15 发布日期:2006-04-15
  • 通讯作者: 林麟, email:linlin@sina.com E-mail:email:linlin@sina.com

A multicentre,randomized,double-blind,placebo-controlled study on the efficacy and safety of interleukin-8 monoclonal antibody cream in the treatment of eczema

CUI Pan-gen1, LIN Lin1, BI Zhi-gang2, LUO Dan2, ZHANG Fu-ren3, TIAN Hong-qing3, LIAN Shi4   

  1. Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
  • Received:2005-12-23 Online:2006-04-15 Published:2006-04-15

PDF (PC)

86

赞

摘要： 目的评价外用抗人白介素8单克隆抗体(抗IL-8单抗)乳膏治疗湿疹的疗效和安全性。方法随机、双盲、安慰剂对照的多中心临床研究,受试者每日外用抗IL-8单抗乳膏或乳膏基质2次,疗程3周,于治疗前及治疗后第1、2、3周各随访1次,进行疗效和安全性评价。结果4个中心共入选湿疹患者229例,纳入疗效分析209例,其中使用抗IL-8单抗乳膏治疗组104例,基质对照组105例。治疗后第1、2、3周,治疗组患者症状/体征的总计分与对照组比较均有明显下降(P<0.05～0.01)。疗程结束时,治疗组和对照组的基本痊愈率分别为27.88%、2.86%;有效率分别为56.73%、15.24%。治疗组的基本痊愈率及有效率均高于对照组(P<0.01)。两组不良反应发生率分别为4.42%和1.79%,差异无统计学意义(P=0.45),主要表现为皮损局部红斑、瘙痒加重或灼热、疼痛等,无系统不良反应。结论抗IL-8单抗乳膏治疗湿疹安全有效。

关键词: 湿疹, 白细胞介素8, 抗体, 单克隆, 随机对照试验

Abstract: Objective To evaluate the efficacy and safety of interleukin-8 monoclonal antibody (IL-8 monAb) cream (45 p.g/g) in the treatment of eczema.Methods A multicentre,randomized,doubleblind,placebo-controlled study was performed.The patients were randomly divided into two groups to receive IL-8 monAb cream (45μg/g) or vehicle,twice daily for 3 weeks.All the patients were evaluated prior to the treatment,and 1,2,3 weeks after the therapy,with clinical effects as well as adverse drug reactions recorded.Results Two hundred and twenty-nine patients were recruited in four clinical centers,and 209 patients completed the trial,of whom 104 were in the treatment group and 105 in the control group.All symptom/sign total scores were significantly decreased (all P<0.05)1,2,3 weeks after the treatment in the treatment group compared with those in the control group.Efficacy assessment based on symptom/sign reducing index (SSRI) showed statistical difference in the cure rates (27.88% vs.2.86%,P<0.05) and responsive rates (56.73% vs.15.24%,P<0.05) between the treatment and control groups.Five (4.71%) patients experienced side effects of burning,local erythema and worsening of itch in the treatment group,and 2 (1.79%)in the control group.The rates of side effects were of no significant difference (P>0.05)between the two groups.No systemic side effects were found.Conclusion Topical use of IL-8 monAb cream (45μg/g) is safe and effective for the treatment of eczema.

Key words: Eczema, Interleukin-8, Antibodies,monoclonal, Randomized controlled trials